Abiopharma

🔍 Jones Kevin Grant (Executive)

Company: DELUXE CORP (DLX)

Report Date: 2026-09-01

Detailed Transactions and Holdings:

• Acquired 54,753 shares of Common Stock (Derivative)
  Date: 2026-09-01 | Code: A | Expires: 2029-08-31 | Exercise: 2026-08-31 | equity_swap_involved: 0 | shares_owned_after: 54,753.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Restricted stock units granted under the Company's Stock Incentive Plan, two-thirds of which vest on the second anniversary of the grant date and the following one-third on the third anniversary of the grant date. Upon vesting, each unit is converted into a share of common stock. Subject to certain exceptions, vesting is contingent upon continued employment.